Introduction. Chlamydia trachomatis (Ct) is an obligate intracellular bacterium, causing a range of diseases in humans. Interactions between chlamydiae and antibiotics have been extensively studied in the past.
Hypothesis/Gap statement: Chlamydial interactions with non-antibiotic drugs have received less attention and warrant further investigations. We hypothesized that selected cytokine inhibitors would alter Ct growth characteristics in HeLa cells.
Aim. To investigate potential interactions between selected cytokine inhibitors and Ct development in vitro.
Methodology. The CCR5 receptor antagonist maraviroc (Mara; clinically used as HIV treatment), the triterpenoid celastrol (Cel; used in traditional Chinese medicine) and the histamine H1 receptor antagonist azelastine (Az; clinically used to treat allergic rhinitis and conjunctivitis) were used in a genital in vitro model of Ct serovar E infecting human adenocarcinoma cells (HeLa).
Results. Initial analyses revealed no cytotoxicity of Mara up to 20 µM, Cel up to 1 µM and Az up to 20 µM. Mara exposure (1, 5, 10 and 20 µM) elicited a reduction of chlamydial inclusion numbers, while 10 µM reduced chlamydial infectivity. Cel 1 µM, as well as 10 and 20 µM Az, reduced chlamydial inclusion size, number and infectivity. Morphological immunofluorescence and ultrastructural analysis indicated that exposure to 20 µM Az disrupted chlamydial inclusion structure. Immunofluorescence evaluation of Cel-incubated inclusions showed reduced inclusion sizes whilst Mara incubation had no effect on inclusion morphology. Recovery assays demonstrated incomplete recovery of chlamydial infectivity and formation of structures resembling typical chlamydial inclusions upon Az removal.
Conclusion. These observations indicate that distinct mechanisms might be involved in potential interactions of the drugs evaluated herein and highlight the need for continued investigation of the interaction of commonly used drugs with Chlamydia and its host.
BommanaS, PolkinghorneA. Mini review: antimicrobial control of chlamydial infections in animals: current practices and issues. Front Microbiol2019; 10:1–9
RowleyJ, VanderHS, KorenrompE, LowN, UnemoM et al.Chlamydia, gonorrhoea, trichomoniasis and syphilis: global prevalence and incidence estimates, 2016. Bull World Health Organ2019; 97:548–562
PhillipsS, QuigleyBL, TimmsP. Seventy years of Chlamydia vaccine research - Limitations of the past and directions for the future. Front Microbiol2019; 10:1–18
BorelN, LeonardC, SladeJ, SchoborgRV. Chlamydial antibiotic resistance and treatment failure in veterinary and human medicine. Curr Clin Microbiol Reports2016; 3:10–18
KuratliJ, PeschT, MartiH, LeonardCA, BlennC et al. Water filtered infrared A and visible light (wIRA/VIS) irradiation reduces Chlamydia trachomatis infectivity independent of targeted cytokine inhibition. Front Microbiol2018; 9:
KannaiyanR, ShanmugamMK, SethiG. Molecular targets of celastrol derived from Thunder of God vine: potential role in the treatment of inflammatory disorders and cancer. Cancer Lett2011; 303:9–20
LeeJY, LeeBH, KimND, LeeJY. Celastrol blocks binding of lipopolysaccharides to a Toll-like receptor4/myeloid differentiation Factor2 complex in a thiol-dependent manner. J Ethnopharmacol2015; 172:254–260 [View Article][PubMed]
BernsteinJA. Azelastine hydrochloride:a review of pharmacology, pharmacokinetics, clinical efficacy and tolerability. Curr Med Res Opin2007; 23:2441–2452
KempurajD, HuangM, Kandere-GrzybowskaK, BasuS, BoucherW et al. Azelastine inhibits secretion of IL-6, TNF-alpha and IL-8 as well as NF-kB activation and intracellular calcium ion levels in normal human mast cells. Int Arch Allergy Immunol2003; 132:231–239 [View Article][PubMed]
LeonardCA, SchoborgRV, BorelN. Productive and penicillin-stressed Chlamydia pecorum infection induces nuclear factor kappa B activation and interleukin-6 secretion in vitro. Front Cell Infect Microbiol2017; 7:
LeonardCA, SchoborgRV, BorelN. Damage/danger associated molecular patterns (DAMPs) modulate Chlamydia pecorum and C. trachomatis serovar e inclusion development in vitro. PLoS One2015; 10:
RahnC, MartiH, FrohnsA, FrohnsF, BlennC et al. Water-filtered infrared a reduces chlamydial infectivity in vitro without causing ex vivo eye damage in pig and mouse models. J Photochem Photobiol B Biol2016; 165:340–350
StaubE, MartiH, BiondiR, LeviA, DonatiM et al. Novel Chlamydia species isolated from snakes are temperature-sensitive and exhibit decreased susceptibility to azithromycin. Sci Rep2018; 8:
OnoriniD, DonatiM, MartiH, BiondiR, LeviA et al. The influence of centrifugation and incubation temperatures on various veterinary and human chlamydial species. Vet Microbiol2019; 233:11–20
StepanenkoAA, DmitrenkoVV. Pitfalls of the MTT assay: direct and off-target effects of inhibitors can result in over/underestimation of cell viability. Gene2015; 574:193–203 [View Article][PubMed]
QuentVMC, LoessnerD, FriisT, ReichertJC, HutmacherDW. Discrepancies between metabolic activity and DNA content as tool to assess cell proliferation in cancer research. J Cell Mol Med2010; 14:1003–1013
de OliveiraCEC, JMMO, Losi GuembarovskiR, de OliveiraKB, ArizaCB et al. CC chemokine receptor 5: the interface of host immunity and cancer. Dis Markers2014
EllwangerJH, Kaminski V deL, AgR, Kulmann-LealB, JabC. CCR5 and CCR5Δ32 in bacterial and parasitic infections: thinking chemokine receptors outside the HIV box. Int J Immunogenet20201–25
CheL-F, ShaoS, WangL. Downregulation of CCR5 inhibits the proliferation and invasion of cervical cancer cells and is regulated by microRNA-107. Exp Ther Med2016; 11:503–509
SalesKJ, AdefuyeA, NicholsonL, KatzAA. CCR5 expression is elevated in cervical cancer cells and is up-regulated by seminal plasma. Mol Hum Reprod2014; 20:1144–1157
OliveAJ, GondekDC, StarnbachMN. Cxcr3 and CCR5 are both required for T cell mediated protection against C. trachomatis infection in the murine genital mucosa. Mucosal Immunol2011; 4:208–216
OgendiBMO, BakshiRK, GuptaK, KapilR, BrownLT et al. T cell phenotypes in women with Chlamydia trachomatis infection and influence of treatment on phenotype distributions. Microbes Infect2018; 20:176–184
BarrEL, OuburgS, IgietsemeJU, MorréSA, OkwanduE et al. Host inflammatory response and development of complications of Chlamydia trachomatis genital infection in CCR5-deficient mice and subfertile women with the CCR5delta32 gene deletion. J Microbiol Immunol Infect2005; 38:244–254
ChunHM, CarpenterRJ, MacalinoGE, Crum-CianfloneNF. The role of sexually transmitted infections in HIV-1 progression: a comprehensive review of the literature. J Sex Transm Dis2013; 2013:1–15
ShrivastavaS, JeengarMK, ReddyVS, ReddyGB, NaiduVGM. Anticancer effect of celastrol on human triple negative breast cancer: possible involvement of oxidative stress, mitochondrial dysfunction, apoptosis and PI3K/Akt pathways. Exp Mol Pathol2015; 98:313–327
CorsonTW, CrewsCM. Molecular understanding and modern application of traditional medicines: triumphs and trials. Cell2007; 130:769–774 [View Article][PubMed]
BaerJT, du LaneyTV, WyrickPB, McCainAS, FischerTA et al. Nuclear Factor–κB activation in endothelium by Chlamydia pneumoniae without active infection. J Infect Dis2003; 188:1094–1097
XiaoY, ZhongY, SuH, ZhouZ, ChiaoP et al. NF-κB activation is not required for Chlamydia trachomatis inhibition of host epithelial cell apoptosis. J Immunol2005; 174:1701–1708
JaquetV, MarcouxJ, ForestE, LeidalKG, McCormickS et al. Nadph oxidase (NOX) isoforms are inhibited by celastrol with a dual mode of action. Br J Pharmacol2011; 164:507–520
BoncompainG, SchneiderB, DelevoyeC, KellermannO, Dautry-VarsatA et al. Production of reactive oxygen species is turned on and rapidly shut down in epithelial cells infected with Chlamydia trachomatis. Infect Immun2010; 78:80–87
OoiN, EadyEA, CoveJH, O’NeillAJ. Redox-Active compounds with a history of human use: antistaphylococcal action and potential for repurposing as topical antibiofilm agents. J Antimicrob Chemother2015; 70:479–488
SmitMJ, BloemersSM, LeursR, TertoolenLG, BastA et al. Short‐term desensitization of the histamine H1 receptor in human HeLa cells: involvement of protein kinase C dependent and independent pathways. Br J Pharmacol1992; 107:448–455 [View Article][PubMed]
El-NakeebMA, Abou-ShleibHM, KhalilAM, OmarHG, El-HalfawyOM. In vitro antibacterial activity of some antihistaminics belonging to different groups against multi-drug resistant clinical isolates. Brazilian J Microbiol2011; 42:980–991
HackstadtT, Scidmore-CarlsonMA, ShawEI, FischerER. The Chlamydia trachomatis IncA protein is required for homotypic vesicle fusion. Cell Microbiol1999; 1:119–130
SuchlandRJ, RockeyDD, BannantineJP, StammWE. Isolates of Chlamydia trachomatis that occupy nonfusogenic inclusions lack IncA, a protein localized to the inclusion membrane. Infect Immun2000; 68:360–367
SlackRJ, HartAD, LuttmannMA, ClarkKL, BeggM. In vitro characterisation of the duration of action of the histamine-1 receptor antagonist azelastine. Eur J Pharmacol [Internet]2011; 670:586–592
GarlandSM, MalattA, TabriziS, GrandoD, LeesMI et al.Chlamydia trachomatis conjunctivitis: prevalence and association with genital tract infection. Med J Aust1995; 162:363–366
Mohamed-NoriegaK, Mohamed-NoriegaJ, Valdés-NavarroMA, Cuervo-LozanoEE, Fernández-EspinosaMC et al. Conjunctival infection with Chlamydia trachomatis in sexual partners of patients with adult inclusion conjunctivitis. Int Ophthalmol2015; 35:179–185
PostemaEJ, RemeijerL, Van Der MeijdenWI. Epidemiology of genital chlamydial infections in patients with chlamydial conjunctivitis; a retrospective study. Genitourin Med1996; 72:203–205
RaulstonJE. Response of Chlamydia trachomatis serovar E to iron restriction vitro and evidence for iron-regulated chlamydial proteins. Infect Immun1997; 65:4539–4547